Nephroprotective effect of GSK-3β inhibition by lithium ions and δ-opioid receptor agonist dalargin on gentamicin-induced nephrotoxicity

Plotnikov, Egor Y.; Гребенчиков, О. А.; Babenko, Valentina A.; Pevzner, Irina B.; Zorova, Ljubava D.; Лихванцев, В. В.; Zorov, Dmitry B.

doi:10.1016/j.toxlet.2013.04.023

Cited by 31 publications

(21 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The initial target of ACR appears to be nerve terminals in both the central and peripheral nervous systems, resulting in autonomic, behavioral, sensory, and motor disturbances [27]. Interestingly, lithium enhances cytoskeleton stability and axonal transport, promotes neurite outgrowth, and increases axonal growth rate [17,28,29]. In consistent with previously studies [30], we found that mice receiving ACR resulted in hind-limb paralysis and walking difficulties.…”

Section: Discussionsupporting

confidence: 88%

Effective Suppression of Acrylamide Neurotoxicity by Lithium in Mouse

et al. 2014

View full text Add to dashboard Cite

The primary objective of this investigation was to assess the neuroprotective efficacy of lithium in an acrylamide (ACR)-induced neuropathy model in mice. In this study, Kunming male mice were administered ACR (25 mg/kg bw, i.p. once a day) with or without lithium (25 mg/kg bw, i.p. once a day) for 2 weeks. All ACR-administered mice exhibited severe symptoms of neuropathy. We found that treatment with lithium effectively alleviated behavioral deficits in animals elicited by acrylamide. Interestingly, the reduction of hippocampal neurogenesis resulting from ACR injection was promoted by administration of lithium. Further, lithium treatment significantly offset ACR-induced depletion in p-GSK-3β (Ser9) levels in hippocampus. Collectively our findings suggest the propensity of lithium to attenuate ACR-induced neuropathy. Further studies are necessary to understand the precise molecular mechanism by which the lithium attenuates neuropathy. Nevertheless, our data clearly demonstrate the beneficial effects of lithium on ACR-induced neuropathy in mice and suggest its possible therapeutic application as an adjuvant in the management of other forms of neuropathy in humans.

show abstract

Section: Discussionsupporting

confidence: 88%

Effective Suppression of Acrylamide Neurotoxicity by Lithium in Mouse

et al. 2014

View full text Add to dashboard Cite

show abstract

“…10,11 In contrast to these adverse effects of lithium treatment, accumulating evidence suggests that the administration of low lithium amounts (,0.6 mM in blood) improves kidney function in different animal nephropathy models. Single-bolus injections or short-term treatment (,1 week) of lithium reduced adriamycin-, LPS-, cisplatin-, gentamicin-, and ischemiainduced AKI, [12][13][14][15][16][17][18] whereas prolonged treatment ($1 month) alleviated kidney damage because of ischemia-reperfusion, hypertension, and the autoimmune disease lupus erythematosus. [19][20][21] To understand these opposing findings, we will first present an overview of renal lithium handling and then, discuss the molecular pathways underlying the toxic and potential therapeutic effects of lithium in the kidney.…”

mentioning

confidence: 99%

Lithium in the Kidney: Friend and Foe?

Alsady

Baumgarten²,

Deen

et al. 2015

JASN

View full text Add to dashboard Cite

Trace amounts of lithium are essential for our physical and mental health, and administration of lithium has improved the quality of life of millions of patients with bipolar disorder for .60 years. However, in a substantial number of patients with bipolar disorder, long-term lithium therapy comes at the cost of severe renal side effects, including nephrogenic diabetes insipidus and rarely, ESRD. Although the mechanisms underlying the lithium-induced renal pathologies are becoming clearer, several recent animal studies revealed that short-term administration of lower amounts of lithium prevents different forms of experimental AKI. In this review, we discuss the knowledge of the pathologic and therapeutic effects of lithium in the kidney. Furthermore, we discuss the underlying mechanisms of these seemingly paradoxical effects of lithium, in which fine-tuned regulation of glycogen synthase kinase type 3, a prime target for lithium, seems to be key. The new discoveries regarding the protective effect of lithium against AKI in rodents call for follow-up studies in humans and suggest that long-term therapy with low lithium concentrations could be beneficial in CKD.

show abstract

“…After 24-hour reperfusion, serum creatinine was significantly increased and the high level of serum creatinine was maintained at 48 hours, suggesting that kidney injury, and not repair or recovery, still predominated. 10 Therefore, the protective effects of lithium on renal function and tubular damage could be the result of suppressing cell death, as suggested by other studies, [6][7][8][9] and not the result of promoting cell proliferation and regeneration. The effect of lithium on renal recovery in ischemic AKI should be better observed within a reperfusion period.48 hours to ensure that the recovery does occur.…”

mentioning

confidence: 87%

“…5 In stark contrast, if used briefly and at low doses, lithium can be renoprotective. In this regard, recent studies have shown the protective effects of lithium in experimental models of AKI induced by renal ischemia-reperfusion, 6,7 nephrotoxin, 8 and endotoxin. 9 In this issue of JASN, Bao et al report that a single dose of lithium given after AKI promotes the recovery and repair of kidneys, whereas de Groot and colleagues show that lithium induces G2 cell cycle arrest in the principal cells of the collecting ducts, which may contribute to the development of NDI.…”

mentioning

confidence: 99%

“…10 It is noteworthy that lithium was given during the recovery phase of AKI in this study, and, therefore, the observed effect is distinct from those shown for lithium given before or during AKI. [6][7][8][9] To further understand how lithium promotes renal recovery after AKI, Bao et al went on to examine glycogen synthase kinase-3b (GSK3b), a direct and relatively specific target of lithium. 10 Not surprisingly, cisplatin led to activation of GSK3b both in kidneys and in cultured renal tubular cells, which was inhibited by postinjury lithium treatment.…”

mentioning

confidence: 99%

See 1 more Smart Citation